Q1 Earnings Estimate for NBIX Issued By Leerink Partnrs

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Neurocrine Biosciences in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per share of $0.91 for the quarter. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.92 per share.

Other analysts also recently issued reports about the company. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Piper Sandler restated an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 23rd. BMO Capital Markets dropped their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Finally, Royal Bank of Canada cut their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $166.10.

Neurocrine Biosciences Trading Down 1.0 %

Shares of NBIX stock opened at $151.82 on Friday. Neurocrine Biosciences has a twelve month low of $110.95 and a twelve month high of $157.98. The stock has a fifty day simple moving average of $136.97 and a two-hundred day simple moving average of $131.62. The stock has a market capitalization of $15.37 billion, a price-to-earnings ratio of 40.70 and a beta of 0.33.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Kevin Charles Gorman sold 146,105 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the completion of the sale, the director now directly owns 514,596 shares in the company, valued at $76,911,518.16. This trade represents a 22.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 214,799 shares of company stock worth $31,513,583. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its holdings in shares of Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after purchasing an additional 539,936 shares in the last quarter. Jennison Associates LLC grew its position in Neurocrine Biosciences by 145.1% during the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock valued at $112,025,000 after buying an additional 485,894 shares during the period. Los Angeles Capital Management LLC increased its holdings in Neurocrine Biosciences by 639.6% in the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after buying an additional 363,863 shares in the last quarter. Braidwell LP raised its position in shares of Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock worth $105,734,000 after acquiring an additional 158,665 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Neurocrine Biosciences by 23.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 533,324 shares of the company’s stock worth $61,450,000 after acquiring an additional 102,715 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.